Jennifer C Wischhusen1, Sayan Mullick Chowdhury2, Taehwa Lee2, Huaijun Wang3, Sunitha Bachawal4, Rammohan Devulapally2, Rayhaneh Afjei5, Uday Kumar Sukumar6, Ramasamy Paulmurugan7. 1. Apoptosis, Cancer and Development Laboratory, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, 69008 Lyon, France; Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. 2. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. 3. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: whjwang@stanford.edu. 4. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: bachawal@stanford.edu. 5. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: rafjei@stanford.edu. 6. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: udkr8817@stanford.edu. 7. Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: paulmur8@stanford.edu.
Abstract
Hepatocellular carcinoma (HCC) is the most common cause of cancer-related mortality, and patients with HCC show poor response to currently available treatments, which demands new therapies. We recently developed a synthetic microRNA-based molecularly targeted therapy for improving HCC response to chemotherapy by eliminating drug resistance. We used ultrasound-targeted microbubble destruction (UTMD) to locally deliver microRNA-loaded nanoparticles to HCC. Since the immune microenvironment plays a crucial role in HCC disease development and response to treatment, and UTMD and microRNAs have the potential to interfere with the immune system, in this study we analyzed the immunomodulatory effects of UTMD and miRNAs in HCC. We used an immunocompetent syngeneic HCC mouse model for the study. We conducted cytokine profiling in tumor, lymph nodes, and serum of animals within the first 24 h of treatment to analyze changes in the level of pro- and antitumoral cytokines. The results showed: (1) Hepa1-6 syngeneic tumors expressed HCC-related cytokines, (2) UTMD-microRNA combination therapy triggered transient cytokine storms, and (3) delivery of microRNA-122 and anti-microRNA-21 affected the immune microenvironment by decreasing the level of GM-CSF in tumors while modulating protumoral IL-1α, IL-1β, IL-5, IL-6 and IL-17 and antitumoral IL-2 and IL-12 in tumor-proximal lymph nodes, and increasing IL-2 in the serum of tumor-bearing mice. Local delivery of targeted therapy by UTMD significantly reduced the concentration of IL-12 and IL-17 in lymph nodes of treated and contralateral tumors suggesting a systemic response. CONCLUSION: UTMD-mediated delivery of microRNA-122 and anti-microRNA-21 modulated the immune microenvironment of Hepa1-6 tumors at the level of cytokine expressions. Exploiting antitumoral immune effects could enhance the therapeutic efficacy of the proposed combination therapy for HCC.
Hepatocellular carcinoma (HCC) is the most common cause of cancer-related mortality, and patients with HCC show poor response to currently available treatments, which demands new therapies. We recently developed a synthetic microRNA-based molecularly targeted therapy for improving HCC response to chemotherapy by eliminating drug resistance. We used ultrasound-targeted microbubble destruction (UTMD) to locally deliver microRNA-loaded nanoparticles to HCC. Since the immune microenvironment plays a crucial role in HCC disease development and response to treatment, and UTMD and microRNAs have the potential to interfere with the immune system, in this study we analyzed the immunomodulatory effects of UTMD and miRNAs in HCC. We used an immunocompetent syngeneic HCCmouse model for the study. We conducted cytokine profiling in tumor, lymph nodes, and serum of animals within the first 24 h of treatment to analyze changes in the level of pro- and antitumoral cytokines. The results showed: (1) Hepa1-6 syngeneic tumors expressed HCC-related cytokines, (2) UTMD-microRNA combination therapy triggered transient cytokine storms, and (3) delivery of microRNA-122 and anti-microRNA-21 affected the immune microenvironment by decreasing the level of GM-CSF in tumors while modulating protumoral IL-1α, IL-1β, IL-5, IL-6 and IL-17 and antitumoral IL-2 and IL-12 in tumor-proximal lymph nodes, and increasing IL-2 in the serum of tumor-bearing mice. Local delivery of targeted therapy by UTMD significantly reduced the concentration of IL-12 and IL-17 in lymph nodes of treated and contralateral tumors suggesting a systemic response. CONCLUSION: UTMD-mediated delivery of microRNA-122 and anti-microRNA-21 modulated the immune microenvironment of Hepa1-6tumors at the level of cytokine expressions. Exploiting antitumoral immune effects could enhance the therapeutic efficacy of the proposed combination therapy for HCC.
Authors: Francesca Fornari; Laura Gramantieri; Catia Giovannini; Angelo Veronese; Manuela Ferracin; Silvia Sabbioni; George Adrian Calin; Gian Luca Grazi; Carlo Maria Croce; Simona Tavolari; Pasquale Chieco; Massimo Negrini; Luigi Bolondi Journal: Cancer Res Date: 2009-07-07 Impact factor: 12.701
Authors: Rammohan Devulapally; Narayana M Sekar; Thillai V Sekar; Kira Foygel; Tarik F Massoud; Jürgen K Willmann; Ramasamy Paulmurugan Journal: ACS Nano Date: 2015-02-23 Impact factor: 15.881
Authors: Naomi S Sta Maria; Samuel R Barnes; Michael R Weist; David Colcher; Andrew A Raubitschek; Russell E Jacobs Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240
Authors: Sukumar Uday Kumar; Arsenii V Telichko; Huaijun Wang; Dongwoon Hyun; Eric G Johnson; Michael S Kent; Robert B Rebhun; Jeremy J Dahl; William T N Culp; Ramasamy Paulmurugan Journal: Adv Ther (Weinh) Date: 2020-11-12